Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206101 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01206101 is a Phase 2 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 3 participants.
The verdict
NCT01206101, a Phase 2 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-03-21 |
| Est. Completion | 2013-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206101
The ClinicalTrials.gov registry entry for NCT01206101 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01206101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206101 about?
NCT01206101 is a clinical study titled "Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation". This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.
What is the current status of trial NCT01206101?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-03-21. Estimated completion is 2013-06-03.
What interventions are being tested in trial NCT01206101?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01206101?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.